BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Rock was most recently clinical project leader and VP of clinical research at MacroGenics Inc. (NASDAQ:MGNX). Brii Biosciences...
...CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Deep Genomics Partner Therapeutics Inc. Brii Biosciences Immatics 8-oxoguanine...
BioCentury | Aug 12, 2020
Product Development

Data Bytes: Regeneron leads COVID-19 antiviral antibody pack

...Sciences and Lilly; Tychan Pte Ltd.; Sinocelltech Ltd. (Shanghai:688520); Celltrion Healthcare Co. Ltd. (KOSDAQ:091990); and Brii Biosciences...
...Inc. Eli Lilly and Co. AbCellera Biologics Inc. Shanghai Junshi Biosciences Co. Ltd. Chinese Academy of Sciences Tychan Pte Ltd. Sinocelltech Ltd. Brii Biosciences Tsinghua...
BioCentury | Apr 22, 2020
Regulation

All for one, one for all: An urgent call to harmonize global drug regulation against COVID-19

...threats, then surely we will all fall. Zhi Hong is co-founder, president and CEO of Brii Biosciences...
...Ltd. Signed commentaries do not necessarily reflect the views of BioCentury. Zhi Hong, CEO and Co-founder, Brii Biosciences...
BioCentury | Apr 16, 2020
Product Development

Master protocols on deck as low enrollment stops Chinese trials of remdesivir

...to enroll COVID-19 patients in trials and assess efficacy. Hong is president and CEO of Brii Biosciences...
BioCentury | Mar 31, 2020
Deals

Brii Bio, Tsinghua, Third People’s Hospital to develop COVID-19 patient-derived neutralizing antibodies

...plan to begin clinical trials in 3Q20, about six months after picking a lead mAb. Brii Biosciences...
...Zhang. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Brii Biosciences Tsinghua...
BioCentury | Mar 27, 2020
Product Development

Fewer is better: master protocols need to replace the deluge of small, inadequate studies for COVID-19

...but should never be at the expense of patient safety and data quality.” Zhi Hong, Brii Biosciences...
...to find the right medicines for the right patients at the earliest time.” Zhi Hong, Brii Biosciences...
...of Brii Biosciences Ltd. Signed commentaries do not necessarily reflect the views of BioCentury. Zhi Hong, Brii Biosciences Ltd. Brii Biosciences COVID-19 coronavirus master...
BioCentury | Feb 27, 2020
Politics, Policy & Law

Plotting a scientific path to counter COVID-19

...mAb could serve as a bridge to a vaccine, Zhi Hong, co-founder and CEO of Brii Biosciences...
...Washington Editor WuXi AppTec CanSino Biologics Inc. Johnson & Johnson Inovio Pharmaceuticals Inc. Vir Biotechnology Inc. AstraZeneca plc Mayo Clinic Moderna Inc. NIH WuXi Biologics Inc. Brii Biosciences Sherlock...
BioCentury | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

...Brii steps into neuroscience Cross-border biotech Brii Biosciences said it will begin developing neuroscience programs as its...
...KOR (OPRK1) - Kappa opioid receptor; TROP2 (TACSTD2; EGP-1) - Tumor-associated calcium signal transducer 2 BioCentury Staff Brii Biosciences Immunomedics...
BioCentury | Nov 21, 2019
Company News

Brii continues to grow infectious disease pipeline via deal with start-up AN2

...a $12 million series A round. Mountain Group Partners led the round with participation from Brii Biosciences...
...begin to look for non-infectious disease programs targeting indications that affect China disproportionately. Hongjiang Li, Staff Writer Brii Biosciences AN2...
BioCentury | Oct 26, 2019
Company News

Oct. 25 Company Quick Takes: Astellas gets European approval for AML therapy; plus Acorda, Amgen, Illumina-PacBio and Qpex-Brii

...due in December. Brii gains China rights to Qpex anti-infective therapies Qpex Biopharma Inc. granted Brii BioSciences...
...145 (Compound #), evolocumab (Generic), Repatha (Other) Illumina Inc. Pacific Biosciences of California Inc. Qpex Biopharma Inc. Astellas Pharma Inc. Brii Biosciences Acorda...
Items per page:
1 - 10 of 23
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Rock was most recently clinical project leader and VP of clinical research at MacroGenics Inc. (NASDAQ:MGNX). Brii Biosciences...
...CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Deep Genomics Partner Therapeutics Inc. Brii Biosciences Immatics 8-oxoguanine...
BioCentury | Aug 12, 2020
Product Development

Data Bytes: Regeneron leads COVID-19 antiviral antibody pack

...Sciences and Lilly; Tychan Pte Ltd.; Sinocelltech Ltd. (Shanghai:688520); Celltrion Healthcare Co. Ltd. (KOSDAQ:091990); and Brii Biosciences...
...Inc. Eli Lilly and Co. AbCellera Biologics Inc. Shanghai Junshi Biosciences Co. Ltd. Chinese Academy of Sciences Tychan Pte Ltd. Sinocelltech Ltd. Brii Biosciences Tsinghua...
BioCentury | Apr 22, 2020
Regulation

All for one, one for all: An urgent call to harmonize global drug regulation against COVID-19

...threats, then surely we will all fall. Zhi Hong is co-founder, president and CEO of Brii Biosciences...
...Ltd. Signed commentaries do not necessarily reflect the views of BioCentury. Zhi Hong, CEO and Co-founder, Brii Biosciences...
BioCentury | Apr 16, 2020
Product Development

Master protocols on deck as low enrollment stops Chinese trials of remdesivir

...to enroll COVID-19 patients in trials and assess efficacy. Hong is president and CEO of Brii Biosciences...
BioCentury | Mar 31, 2020
Deals

Brii Bio, Tsinghua, Third People’s Hospital to develop COVID-19 patient-derived neutralizing antibodies

...plan to begin clinical trials in 3Q20, about six months after picking a lead mAb. Brii Biosciences...
...Zhang. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Sandi Wong, Assistant Editor Brii Biosciences Tsinghua...
BioCentury | Mar 27, 2020
Product Development

Fewer is better: master protocols need to replace the deluge of small, inadequate studies for COVID-19

...but should never be at the expense of patient safety and data quality.” Zhi Hong, Brii Biosciences...
...to find the right medicines for the right patients at the earliest time.” Zhi Hong, Brii Biosciences...
...of Brii Biosciences Ltd. Signed commentaries do not necessarily reflect the views of BioCentury. Zhi Hong, Brii Biosciences Ltd. Brii Biosciences COVID-19 coronavirus master...
BioCentury | Feb 27, 2020
Politics, Policy & Law

Plotting a scientific path to counter COVID-19

...mAb could serve as a bridge to a vaccine, Zhi Hong, co-founder and CEO of Brii Biosciences...
...Washington Editor WuXi AppTec CanSino Biologics Inc. Johnson & Johnson Inovio Pharmaceuticals Inc. Vir Biotechnology Inc. AstraZeneca plc Mayo Clinic Moderna Inc. NIH WuXi Biologics Inc. Brii Biosciences Sherlock...
BioCentury | Dec 4, 2019
Company News

Dec. 3 Company Quick Takes: Brii adds neuroscience focus; plus Immunomedics, Hanmi-Rapt, Luye-Boan and Cara

...Brii steps into neuroscience Cross-border biotech Brii Biosciences said it will begin developing neuroscience programs as its...
...KOR (OPRK1) - Kappa opioid receptor; TROP2 (TACSTD2; EGP-1) - Tumor-associated calcium signal transducer 2 BioCentury Staff Brii Biosciences Immunomedics...
BioCentury | Nov 21, 2019
Company News

Brii continues to grow infectious disease pipeline via deal with start-up AN2

...a $12 million series A round. Mountain Group Partners led the round with participation from Brii Biosciences...
...begin to look for non-infectious disease programs targeting indications that affect China disproportionately. Hongjiang Li, Staff Writer Brii Biosciences AN2...
BioCentury | Oct 26, 2019
Company News

Oct. 25 Company Quick Takes: Astellas gets European approval for AML therapy; plus Acorda, Amgen, Illumina-PacBio and Qpex-Brii

...due in December. Brii gains China rights to Qpex anti-infective therapies Qpex Biopharma Inc. granted Brii BioSciences...
...145 (Compound #), evolocumab (Generic), Repatha (Other) Illumina Inc. Pacific Biosciences of California Inc. Qpex Biopharma Inc. Astellas Pharma Inc. Brii Biosciences Acorda...
Items per page:
1 - 10 of 23